Deafness affects 5% of the world's population, yet there is a lack of treatments to prevent
hearing loss due to genetic causes.
Norrie disease is a recessive X-linked disorder, caused by NDP gene mutation. It manifests as
blindness at birth and progressive
sensorineural hearing loss, leading to debilitating dual sensory deprivation. To develop a gene
therapy, we used a
Norrie disease mouse model (Ndptm1Wbrg ), which recapitulates abnormal
retinal vascularisation and progressive
hearing loss. We delivered human NDP
cDNA by
intravenous injection of adeno-associated viral vector (AAV)9 at neonatal, juvenile and young adult pathological stages and investigated its
therapeutic effects on the retina and cochlea. Neonatal treatment prevented the death of the sensory cochlear hair cells and rescued
cochlear disease biomarkers as demonstrated by RNAseq and physiological measurements of auditory function.
Retinal vascularisation and electroretinograms were restored to normal by neonatal treatment. Delivery of NDP gene therapy after the onset of the degenerative
inner ear disease also ameliorated the cochlear pathology, supporting the feasibility of a clinical treatment for progressive
hearing loss in people with
Norrie disease.